PI Industries had a weak start to FY27 as lower export sales, soft demand and higher raw material costs hurt its financial performance. The company released the transcript of its Q1 FY27 earnings call held on August 12, 2026. The call covered the results for the quarter ended June 30, 2026, along with the company’s plans for the rest of the year.
Consolidated revenue fell 10% year-on-year to ₹17,023 Mn from ₹19,023 Mn in Q1 FY26. EBITDA dropped 29% to ₹3,693 Mn from ₹5,219 Mn. EBITDA margin fell to 21.69% from 27.46%, a decline of 577 basis points. Net profit fell 39% to ₹2,442 Mn from ₹4,000 Mn in the same quarter last year.
The main weakness came from the export business. This part of PI Industries has a large share of total revenue, so the decline had a clear effect on the overall result.
Export Business Remains Under Pressure
Export revenue fell 13.3% to ₹13,542 Mn in Q1 FY27. Agchem export volumes fell 8% year-on-year. The company faced generic competition, weak demand and lower commodity prices across key markets.
This pressure is not limited to one customer or one product. The global agrochemical market is still in a difficult phase. Lower prices and high inventory levels have made customers more careful with new orders. PI Industries also faced higher input costs due to geopolitical tensions.
Management said its differentiated product portfolio can help reduce some of this pressure. However, generic products remain under strong price pressure. The company sees its new products and new molecules as an important way to improve the export business over time.
Domestic Business Shows Better Resilience
The domestic business gave a more positive picture. Domestic revenue rose 2.8% to ₹3,481 Mn. Domestic volume grew by about 12%.
A major part of this improvement came from biologicals. The biologicals business grew by more than 50% year-on-year. This shows that the company’s newer products can create growth even when the core agrochemical market faces pressure.
Management also spoke about the wider biologicals platform. PI Industries has completed more than 500 field trials and has had more than 1,000 grower engagements. One of its key products is a foliar application nematode product. The product has registrations in Brazil, Mexico and the US.
This area can become more important for PI Industries as farmers and regulators seek newer solutions. The company sees biologicals as one of its longer-term growth areas.
Agchem Segment Sees Lower Profit
The agrochemicals segment, which includes CSM exports, domestic agri brands and biologicals, reported revenue of ₹16,488 Mn in Q1 FY27. This was lower than ₹18,287 Mn in Q1 FY26.
Profit before tax for the segment fell to ₹3,835 Mn from ₹5,656 Mn. Generic competition and a delayed monsoon pattern, which affected Kharif sowing in India, added to the pressure.
The company also saw higher overheads. These rose 5% to ₹5,984 Mn. Overall gross margin fell 69 basis points to 57%, with higher raw material prices also affecting the result.
The numbers show that the problem was not only lower sales. Lower margins and higher costs also reduced the company’s profit.
Pharma Business Faces Order Timing Issues
PI Industries’ pharma business, through PI Health Sciences, also had a weak quarter. Revenue fell 25% to ₹542 Mn.
Management said the fall was due to order book phasing and customer delivery schedules. It did not point to a structural problem in the business. Still, the pharma unit reported a pre-tax loss of ₹816 Mn, compared with a loss of ₹760 Mn in Q1 FY26.
There are some positive signs in the pharma pipeline. Three new molecules were commercialized in exports, while a new peptide-based biological product was launched in the US. These products could support the business as the portfolio gets larger.
Strong Cash Flow Offers Some Comfort
One of the more positive points from the quarter was cash flow. Operating cash flow stood at ₹6,395 Mn in Q1 FY27, despite the sharp fall in net profit.
The company also improved its trade working capital. The working capital cycle fell by 19 days to 120 days. This is important because it shows that the lower profit did not come with a major cash flow problem.
PI Industries ended the quarter with a net cash position of ₹37,939 Mn. Shareholders’ funds rose to ₹1,14,683 Mn. The debt-to-equity ratio remained very low at 0.02.
The company spent ₹2,685 Mn on capital expenditure in Q1 FY27. The money went toward manufacturing capacity and research and development.
Five New Products Planned for FY27
PI Industries plans to launch five new products in FY27. These launches are important for the company because new products can help reduce its dependence on older molecules that face generic competition.
Management also highlighted its pipeline of about 90 molecules. Most of these are in agrochemicals, with a significant presence in biologicals and electronics.
One important molecule is Pioxaniliprole, an insecticide discovered in India. The company expects its domestic launch soon, subject to regulatory approvals. This molecule is important because it shows PI Industries’ shift toward its own innovation rather than only contract manufacturing.
Electronics Chemicals Add a New Growth Area
PI Industries is also building its electronic chemicals business. Management confirmed that commercial supplies have started in this area.
The company continues to invest in this segment to support next-generation technologies. Electronic chemicals can offer a new source of growth outside the traditional agrochemical market.
This part of the business is still at an early stage, so its near-term effect on revenue may remain limited. However, the company sees it as part of its wider plan to build several growth platforms.
CRDMO Needs More Time
The pharma CRDMO business remains another key long-term focus. Management said the model has a long gestation period. The current losses are linked to early investment in regulatory systems and capabilities.
PI Industries is working to build relationships with biotech companies and large pharma companies through global business development. Management expects volatility to reduce as the portfolio grows.
This means investors may need patience with the pharma business. The company is spending today with the aim of creating a larger business over the longer term.
Strong Balance Sheet Supports the Next Phase
The Q1 FY27 results were weak, but PI Industries still has a strong balance sheet. The ₹37,939 Mn net cash position gives the company room to invest in new businesses, products and capacity without taking on large debt.
The key question now is how fast the export business can recover. New product launches, biologicals, electronic chemicals and the CRDMO platform can support future growth, but some of these areas need time.
For FY27, the company therefore has a mixed picture. The core export business faces pressure, while the domestic business and newer platforms show better signs. The five planned product launches and the wider molecule pipeline could become important growth drivers.
What Investors Should Watch Next
The next few quarters will show whether the export market starts to recover and whether new products can offset price pressure. Investors should also watch gross margins, export volumes, pharma order flow and the pace of growth in biologicals.
The Q1 FY27 call does not show a company without growth options. Instead, it shows a business in a difficult market cycle while it builds new sources of growth.
PI Industries has strong cash reserves, a low debt burden and a large product pipeline. At the same time, near-term earnings remain under pressure due to weak exports, lower prices and higher input costs. The balance between these two sides will be the key story for PI Industries through FY27.
